Advaxis Cancer Immunotherapy on Hold Due to Patient Death
| 10/06/15 - 05:07 PM EDT
PRINCETON, N.J. ( TheStreet) -- The U.S. Food and Drug Administration placed a halt on clinical trials involving a cancer immunotherapy from Advaxis (ADXS) because of concerns a bacteria used to deliver the drug may have contributed to a patient death.
Advaxis believes the patient died due to the progression of cervical cancer, but FDA is asking for additionalinformation to confirm the company's experimental therapy, axalimogene filolisbac, played no role. Until the FDA's concerns are resolved, four clinical trials involving Advaxis' axalimogene filolisbac are on clinical hold.
thanks. With that close looks like she wants to run bad.
Im in boys
NFLX is expanding to complete its 200-country takeover by 2016,APPL Talking Yrs Away
Bloombergs a scam lol makes up headlines - man talk about desperation
Is Correct- Bought My Shares For It : )))))
Sentiment: Strong Buy